Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 3, 2025
Daily News
October 3, 2025
- Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
- Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
October 3, 2025
- Argenx Puts Japan at Core of Global Innovation Strategy
October 3, 2025
- Panel Split on Delisting OTC-Like Drugs from Insurance Coverage
October 3, 2025
- Daiichi Sankyo Opens Third Overseas Research Hub in San Diego
October 3, 2025
- Enhertu Accepted for US Review in Pre-Surgery Setting for Early Breast Cancer
October 3, 2025
- Ziftomenib Given in New AML Cohort in US PI Trial: Kura/Kyowa Kirin
October 3, 2025
- HIV Support Groups Call for Stronger Mail-In Testing System in Japan
October 3, 2025
- SanBio’s Akuugo Set for Re-Review on Oct. 16, Shipment Decision Nears
October 3, 2025
- Dayvigo, Jardiance Keep Up Strong Promotion in August: Intage
October 3, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…